loading
Wave Life Sciences Ltd stock is traded at $5.86, with a volume of 578.71K. It is up +0.00% in the last 24 hours and up +5.21% over the past month. WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$5.86
Open:
$5.9
24h Volume:
578.71K
Relative Volume:
0.67
Market Cap:
$730.96M
Revenue:
$113.31M
Net Income/Loss:
$-57.51M
P/E Ratio:
-4.3088
EPS:
-1.36
Net Cash Flow:
$-20.55M
1W Performance:
+14.23%
1M Performance:
+5.21%
6M Performance:
-14.26%
1Y Performance:
+17.43%
1-Day Range:
Value
$5.765
$5.97
1-Week Range:
Value
$5.31
$6.15
52-Week Range:
Value
$3.50
$7.67

Wave Life Sciences Ltd Stock (WVE) Company Profile

Name
Name
Wave Life Sciences Ltd
Name
Phone
617-949-2900
Name
Address
7 STRAITS VIEW, SINGAPORE
Name
Employee
268
Name
Twitter
@WAVELifeSci
Name
Next Earnings Date
2024-08-08
Name
Latest SEC Filings
Name
WVE's Discussions on Twitter

Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-05-23 Initiated Raymond James Outperform
May-24-23 Downgrade Jefferies Buy → Hold
Dec-15-20 Resumed H.C. Wainwright Buy
Oct-23-20 Initiated RBC Capital Mkts Sector Perform
Dec-31-19 Downgrade SVB Leerink Outperform → Mkt Perform
Nov-01-19 Initiated Guggenheim Buy
Jul-15-19 Initiated Cowen Market Perform
Apr-17-19 Reiterated H.C. Wainwright Buy
Aug-07-18 Initiated Stifel Buy
Jul-23-18 Initiated H.C. Wainwright Buy
Mar-19-18 Reiterated Mizuho Buy
Feb-15-17 Initiated H.C. Wainwright Buy
Nov-10-16 Resumed Leerink Partners Outperform
Dec-07-15 Initiated JMP Securities Mkt Outperform
Dec-07-15 Initiated Jefferies Buy
Dec-07-15 Initiated Leerink Partners Outperform
Dec-07-15 Initiated Sun Trust Rbsn Humphrey Buy
View All

Wave Life Sciences Ltd Stock (WVE) Latest News

pulisher
Sep 14, 2024

North America Dystrophin Market By Application – news - Vaccine Storage & Packaging ...

Sep 14, 2024
pulisher
Sep 14, 2024

(WVE) Proactive Strategies - Stock Traders Daily

Sep 14, 2024
pulisher
Sep 13, 2024

Spinal Muscular Atrophy Medicine Industry: 95656.60mn Insights from Latest Research Report on Business Opportunities by (2024-2034) – Talented India - Talented India

Sep 13, 2024
pulisher
Sep 11, 2024

Alpha-1 Antitrypsin Deficiency Market Expected to Experience - openPR

Sep 11, 2024
pulisher
Sep 11, 2024

How should investors view Wave Life Sciences Ltd. (WVE)? - US Post News

Sep 11, 2024
pulisher
Sep 11, 2024

Wave Life Sciences initiated with Overweight at J.P. Morgan - MSN

Sep 11, 2024
pulisher
Sep 10, 2024

Wave Life Sciences Ltd. (WVE) Stock: A Comprehensive 52-Week Review - The InvestChronicle

Sep 10, 2024
pulisher
Sep 10, 2024

Wave Life Sciences (NASDAQ:WVE) Shares Gap Up to $5.13 - MarketBeat

Sep 10, 2024
pulisher
Sep 10, 2024

Wave Life Sciences (NASDAQ:WVE) Receives New Coverage from Analysts at JPMorgan Chase & Co. - Defense World

Sep 10, 2024
pulisher
Sep 09, 2024

Wave Life Sciences Ltd. (NASDAQ:WVE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Sep 09, 2024
pulisher
Sep 09, 2024

JPMorgan Chase & Co. Begins Coverage on Wave Life Sciences (NASDAQ:WVE) - MarketBeat

Sep 09, 2024
pulisher
Sep 09, 2024

JP Morgan Initiates Coverage of Wave Life Sciences (WVE) with Overweight Recommendation - MSN

Sep 09, 2024
pulisher
Sep 09, 2024

Wave Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World

Sep 09, 2024
pulisher
Sep 08, 2024

Emerald Advisers LLC Makes New $12.44 Million Investment in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat

Sep 08, 2024
pulisher
Sep 08, 2024

Broker Revenue Forecasts For Wave Life Sciences Ltd. (NASDAQ:WVE) Are Surging Higher - Simply Wall St

Sep 08, 2024
pulisher
Sep 05, 2024

Wave Life Sciences Ltd. (WVE)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex

Sep 05, 2024
pulisher
Sep 05, 2024

WVE Stock Sees Decline of Approximately -9.38% in Last Five Days - Knox Daily

Sep 05, 2024
pulisher
Sep 05, 2024

WVE’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle

Sep 05, 2024
pulisher
Sep 04, 2024

Nucleic Acid Based Gene Therapy Market Size, Share, Growth, Trends, Forecast to 2033 - WhaTech

Sep 04, 2024
pulisher
Sep 04, 2024

Wave Life Sciences (NASDAQ:WVE) Stock Price Down 3.4% - MarketBeat

Sep 04, 2024
pulisher
Sep 03, 2024

WAVE Life Sciences maintain Buy rating from Jones Trading with consistent target - Investing.com India

Sep 03, 2024
pulisher
Sep 03, 2024

Oligonucleotide Therapy Global Market Projected Growth Outlined by Industry Trends Growth Drivers and Futur... - WhaTech

Sep 03, 2024
pulisher
Sep 02, 2024

Duchenne Muscular Dystrophy Drugs Market Size, Regional Demand, Trends and Forecast to 2024-2032 - அக்னி செய்திகள்

Sep 02, 2024
pulisher
Aug 31, 2024

Wave Life Sciences (NASDAQ:WVE) Shares Cross Below Fifty Day Moving Average of $5.72 - MarketBeat

Aug 31, 2024
pulisher
Aug 31, 2024

Wave Life Sciences (NASDAQ:WVE) Stock Passes Below Fifty Day Moving Average of $5.72 - Defense World

Aug 31, 2024
pulisher
Aug 28, 2024

Analyzing Wave Life Sciences Ltd. (WVE) After Recent Trading Activity - Knox Daily

Aug 28, 2024
pulisher
Aug 24, 2024

Insider Selling: President and CEO Paul Bolno Sells 48,366 Shares of WAVE Life Sciences Ltd (WVE) - Yahoo Finance

Aug 24, 2024
pulisher
Aug 24, 2024

Insider Selling: President and CEO Paul Bolno Sells 48,366 Shares of WAVE Life Sciences Ltd (WVE) - Yahoo Finance UK

Aug 24, 2024
pulisher
Aug 24, 2024

Insider Selling: President and CEO Paul Bolno Sells 48,366 Shares of WAVE Life Sciences Ltd (WVE) - GuruFocus.com

Aug 24, 2024
pulisher
Aug 23, 2024

Paul Bolno Sells 48,366 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) Stock - MarketBeat

Aug 23, 2024
pulisher
Aug 23, 2024

WVE: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle

Aug 23, 2024
pulisher
Aug 23, 2024

There is no way Wave Life Sciences Ltd. (WVE) can keep these numbers up - SETE News

Aug 23, 2024
pulisher
Aug 23, 2024

Ratio Revelations: Wave Life Sciences Ltd. (WVE)’s Financial Metrics in the Spotlight - The Dwinnex

Aug 23, 2024
pulisher
Aug 23, 2024

Duchenne Muscular Dystrophy Clinical Trials Analysis 2024: FDA - openPR

Aug 23, 2024
pulisher
Aug 21, 2024

Wave Life Sciences (NASDAQ:WVE) Trading Down 3.2% - MarketBeat

Aug 21, 2024
pulisher
Aug 20, 2024

Examining Wave Life Sciences Ltd. (WVE) more closely is necessary - US Post News

Aug 20, 2024
pulisher
Aug 19, 2024

SG Americas Securities LLC Purchases Shares of 133,827 Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat

Aug 19, 2024
pulisher
Aug 18, 2024

(WVE) Investment Analysis - Stock Traders Daily

Aug 18, 2024
pulisher
Aug 16, 2024

Vanguard Group Inc. Increases Stake in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat

Aug 16, 2024
pulisher
Aug 15, 2024

Taking on analysts’ expectations and winning: Wave Life Sciences Ltd. (WVE) - SETE News

Aug 15, 2024
pulisher
Aug 15, 2024

Vanguard Group Inc. Buys 521,665 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World

Aug 15, 2024
pulisher
Aug 15, 2024

Wave Life Sciences Ltd. (NASDAQ:WVE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Aug 15, 2024
pulisher
Aug 15, 2024

Wave Life Sciences Ltd. (NASDAQ:WVE) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Aug 15, 2024
pulisher
Aug 14, 2024

Frontotemporal Dementia Market to Show Remarkable Growth - openPR

Aug 14, 2024
pulisher
Aug 14, 2024

Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating - Benzinga

Aug 14, 2024
pulisher
Aug 13, 2024

FDA grants rare pediatric disease designation to Wave's DMD drug - Investing.com India

Aug 13, 2024
pulisher
Aug 13, 2024

Market Update: Wave Life Sciences Ltd. (WVE) Sees Negative Movement, Closing at 5.37 - The Dwinnex

Aug 13, 2024
pulisher
Aug 13, 2024

Wave Life Sciences expands equity incentive plan by 5 million shares - Investing.com Australia

Aug 13, 2024
pulisher
Aug 13, 2024

Examining Wave Life Sciences Ltd. (WVE) stock is warranted - US Post News

Aug 13, 2024
pulisher
Aug 13, 2024

Wave Life Sciences expands equity incentive plan by 5 million shares - Investing.com India

Aug 13, 2024
pulisher
Aug 13, 2024

FDA grants rare pediatric disease designation to Wave's DMD drug - Investing.com

Aug 13, 2024

Wave Life Sciences Ltd Stock (WVE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$26.90
price up icon 1.55%
$198.49
price up icon 1.13%
$31.93
price up icon 16.49%
$123.40
price up icon 17.52%
$68.28
price down icon 2.01%
$538.01
price up icon 0.42%
Cap:     |  Volume (24h):